Study wrapper · #1375
Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.
Patel KS, Fakhoury B, Parmar K, et al. Intestinal research. 2026.
DOI: 10.5217/ir.2026.00152PubMed: 42717572
Editor's note
Propensity-matched with 3,042 patients per arm — sizable for an IBD pharmacoepidemiology question — but retrospective, so residual confounding, including differential weight loss and adherence, can't be excluded. The effect is modest (aHR 0.81 for IV steroids) and drives the composite endpoint largely on its own. The authors appropriately call for prospective validation before drawing mechanistic conclusions.
Plain-language abstract
In a large US database study, patients with inflammatory bowel disease taking tirzepatide had about a 19% lower risk of needing IV steroids over 18 months than matched patients on GLP-1 drugs, with no difference in surgeries, ER visits, or hospitalizations. Safety outcomes were similar between the two groups.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026